N-desmethyl Imatinib

N-desmethyl Imatinib

CAT N°: 16947
Price:

From 57.00 48.45

N-desmethyl Imatinib is a major active metabolite of imatinib (Item No. 13139), an anticancer agent that selectively targets tyrosine kinases, including Bcr-ABL, platelet-derived growth factor receptor (PDGFR), and KIT.{17064,17065} N-desmethyl Imatinib is formed when imatinib undergoes demethylation by the cytochrome P450 (CYP) isomer CYP3A4.{40229} N-desmethyl Imatinib has the same in vitro potency at Bcr-ABL kinase as imatinib (IC50 = 38 nM for both) but is only present in plasma at 10-15% of the levels of imatinib, indicating the majority of the anticancer activity can be attributed to the parent compound.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(1-piperazinylmethyl)-benzamide
  • Correlated keywords
    • CGP-74588 CGP74588 50900 STI50900 Norimatinib Gleevev anti-cancer Desmethylimatinib Nor-imatinib desmethylgleevec
  • Product Overview:
    N-desmethyl Imatinib is a major active metabolite of imatinib (Item No. 13139), an anticancer agent that selectively targets tyrosine kinases, including Bcr-ABL, platelet-derived growth factor receptor (PDGFR), and KIT.{17064,17065} N-desmethyl Imatinib is formed when imatinib undergoes demethylation by the cytochrome P450 (CYP) isomer CYP3A4.{40229} N-desmethyl Imatinib has the same in vitro potency at Bcr-ABL kinase as imatinib (IC50 = 38 nM for both) but is only present in plasma at 10-15% of the levels of imatinib, indicating the majority of the anticancer activity can be attributed to the parent compound.

We also advise you